EP1246902A2 - Lignee cellulaire pour preparer et produire des vecteurs d'adenovirus ovins - Google Patents

Lignee cellulaire pour preparer et produire des vecteurs d'adenovirus ovins

Info

Publication number
EP1246902A2
EP1246902A2 EP01905667A EP01905667A EP1246902A2 EP 1246902 A2 EP1246902 A2 EP 1246902A2 EP 01905667 A EP01905667 A EP 01905667A EP 01905667 A EP01905667 A EP 01905667A EP 1246902 A2 EP1246902 A2 EP 1246902A2
Authority
EP
European Patent Office
Prior art keywords
cell line
adenoviruses
sheep
hvo
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01905667A
Other languages
German (de)
English (en)
Inventor
Christian Hofmann
Moritz Hillgenberg
Peter LÖSER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Develogen AG
Original Assignee
Develogen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen AG filed Critical Develogen AG
Publication of EP1246902A2 publication Critical patent/EP1246902A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
    • C12N2710/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
    • C12N2710/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
    • C12N2710/10151—Methods of production or purification of viral material
    • C12N2710/10152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Definitions

  • the invention relates to the sheep embryo cell line HVO-1 56 (DSM ACC2440) or cell lines derived therefrom and their use for the production and multiplication of sheep adenoviruses, in particular recombinant sheep adenoviruses which are derived from the isolate OAV 287.
  • Genetic defects can cause diseases such as cancer, cystic fibrosis, muscular dystrophy and others.
  • a large number of gene therapy methods have already been proposed to remedy these genetic defects.
  • Successful gene therapy is based on methods for the production of vectors which can introduce therapeutic genes into the genetically defective target cells with sufficient efficiency.
  • viruses for gene therapy.
  • human viruses with low pathogenic potential such as attenuated adenoviruses, adeno-associated viruses, herpes viruses and retroviruses have been used as vectors. It was recognized that none of the systems mentioned can be used for any gene therapy applications.
  • a general argument against successful use of human viral vectors in humans is endemic pre-existing immunity in most people, which was caused by infection with these viruses in childhood.
  • Viral vectors that are able to overcome this pre-existing immunity in humans are based, inter alia, on sheep adenoviruses, in particular the sheep adenovirus isclate OAV 287.
  • sheep adenoviruses in particular the sheep adenovirus isclate OAV 287.
  • This virus and the use of recombinant variants thereof for gene therapy are described in WO96 / 03508 and WO97 / 06826.
  • the currently only available Schafungen cell line CSL 503 (Pye et al., Austr. Vet. J. 66: 231-232 (1 989)) is only slightly efficient.
  • this cell line when this cell line is transfected with recombinant sheep adenovirus DNA, only a small number of recombinant sheep adenoviruses are produced.
  • the cell line CSL 503 only has a relatively short lifespan of usually less than 20 passages and therefore only allows a comparatively low virus replication rate.
  • sheep embryo cell lines in particular the sheep embryo cell line HVO-1 56 (DSM ACC2440) or cell lines derived therefrom enable such an efficient multiplication of adenoviruses. These cells are characterized by a long lifespan (at least 40 times passability corresponding to> 100 generations), good transfectability with recombinant DNA, high efficiency in the production of recombinant sheep adenoviruses and a high rate of replication of recombinant sheep adenoviruses.
  • the invention thus relates to the sheep embryo cell line HVO-1 56 (DSM ACC2440) or a cell line derived therefrom.
  • This cell line was deposited on December 22, 1 999 with the DSMZ (German Collection of Microorganisms and Cell Cultures GmbH), Mascheroder Weg 1 b, D-381 24 Braunschweig in accordance with the provisions of the Budapest Treaty.
  • the stored cell line or cell lines derived from it for example, by subcloning, and other sheep embryo cell lines are suitable for production or / and multiplication of adenoviruses, in particular of sheep adenoviruses, such as of sheep adenoviruses of the isolate OAV 287 and recombinant viruses derived therefrom.
  • Figure 1 the morphology of HVO-1 56 cells (DSM ACC2440) before cultivation (A) and after cultivation for 40 passages (B),
  • HVO-1 56 cells were cultured in DMEM at 37 (or 40) ° C for up to 40 passages. The cells were analyzed morphologically before and after cultivation. There were no changes in the morphological appearance, as can be seen from a comparison of Figures 1 A (morphology before cultivation) and 1 B (morphology after 40 passages).
  • the amount of recombinant sheep adenovirus OAVhAAT produced in HVO-1 56 cells was analyzed depending on the amount of virus used. 3 x 10 5 cells were infected at MOIs (multiplicities of infection) of 0.2 / 2/10 and the titer of the total virus produced was described by an end point after 48 hours as described by Hofmann et al., Supra -Dilution assay determined.
  • the count (dark nuclei) showed a transfection of 80%.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne la lignée cellulaire de l'embryon d'ovin HVO-156 (DSM ACC2440) ou des lignées cellulaires qui en sont dérivées et leur utilisation pour préparer et multiplier des adénovirus ovins, notamment des adénovirus ovins recombinés, dérivés de l'isolat OAV 287.
EP01905667A 2000-01-14 2001-01-12 Lignee cellulaire pour preparer et produire des vecteurs d'adenovirus ovins Withdrawn EP1246902A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10001390A DE10001390A1 (de) 2000-01-14 2000-01-14 Zelllinie zur Herstellung und Produktion von Schafadenovirusvektoren
DE10001390 2000-01-14
PCT/EP2001/000366 WO2001051606A2 (fr) 2000-01-14 2001-01-12 Lignee cellulaire pour preparer et produire des vecteurs d'adenovirus ovins

Publications (1)

Publication Number Publication Date
EP1246902A2 true EP1246902A2 (fr) 2002-10-09

Family

ID=7627547

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01905667A Withdrawn EP1246902A2 (fr) 2000-01-14 2001-01-12 Lignee cellulaire pour preparer et produire des vecteurs d'adenovirus ovins

Country Status (7)

Country Link
US (1) US6821777B2 (fr)
EP (1) EP1246902A2 (fr)
JP (1) JP2003519485A (fr)
AU (1) AU778500B2 (fr)
CA (1) CA2397003A1 (fr)
DE (1) DE10001390A1 (fr)
WO (1) WO2001051606A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322197A2 (fr) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Compositions pharmaceutiques comportant de la desmopressine faiblement dosee

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM710194A0 (en) * 1994-07-26 1994-08-18 Commonwealth Scientific And Industrial Research Organisation Virus vector

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0151606A3 *

Also Published As

Publication number Publication date
AU3369301A (en) 2001-07-24
WO2001051606A3 (fr) 2002-03-28
AU778500B2 (en) 2004-12-09
DE10001390A1 (de) 2001-07-19
US20030003566A1 (en) 2003-01-02
WO2001051606A2 (fr) 2001-07-19
CA2397003A1 (fr) 2001-07-19
US6821777B2 (en) 2004-11-23
JP2003519485A (ja) 2003-06-24

Similar Documents

Publication Publication Date Title
DE69126606T2 (de) Vakzine
DE69637432T2 (de) Adenovirale vektoren für die gentherapie
DE60112050T2 (de) Rekombinantes influenza a virus
DE19735593C2 (de) Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie
DE69120662T2 (de) Rekombinante poxvirusinnenkerne
DE69534669T2 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
EP0606280B1 (fr) Nouveaux composes conjugues pour l'introduction d'acide nucleique dans des cellules eucariotes superieures
DE60027870T2 (de) Genetische manipulierte herpesviren zur behandlung von tumoren
DE69331526T2 (de) Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel
DE68927073T2 (de) Modifiziertes Baculovirus,Herstellung und Verwendung als Expressionsvektor
DE69534166T2 (de) Rekombinanter adenovirus und methoden zu dessen verwendung
DE69531387T2 (de) Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
EP1397499B1 (fr) Plasmides auxiliaires aav permettant l'encapsidation sans virus auxiliaire et le pseudotypage de vecteurs aav
DE895535T1 (de) Grippevirus, repliziert in säugerzellkultur, und impfstoffherstellung
DE69431046T2 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
DE69736838T2 (de) Herpesvirus saimiri als viraler vektor
DE69333751T2 (de) Nicht-verbreitendes lebendes herpesvirusvakzin
DE4407859C1 (de) Vektor für die leberspezifische Gentherapie
DD232822A5 (de) Verfahren zur herstellung eines viruspraeparates gegen die mareksche gefluegelkrankheit
DE69535093T2 (de) Defektive rekombinante adenoviren mit einem inaktivierten gen iv a 2
EP1246902A2 (fr) Lignee cellulaire pour preparer et produire des vecteurs d'adenovirus ovins
DE69629819T2 (de) Avirulente herpetische viren verwendbar als tumorzerstörendes agens und impfstoff
DE69027695T2 (de) Rekombinanter Cytomegalovirus-Impfstoff
DE69733948T2 (de) In vivo herstellung von replicativen molekülen
DE69912118T2 (de) Entomopoxvirus vektor zur abgabe und expression von dns heterologen in vertebratenzellen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020711

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DEVELOGEN AKTIENGESELLSCHAFT

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070801